How to buy aTyr Pharma stock

aTyr Pharma, Inc is a biotechnology business based in the US. aTyr Pharma shares (LIFE) are listed on the NASDAQ and all prices are listed in US Dollars. aTyr Pharma employs 40 staff and has a trailing 12-month revenue of around 0.00.

aTyr Pharma share price

Use our graph to track the performance of LIFE stocks over time.

aTyr Pharma shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$2.93 - $7.93
50-day moving average	$4.47
200-day moving average	$4.20
Wall St. target price	$15.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-10.21

Buy aTyr Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy aTyr Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of aTyr Pharma, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

aTyr Pharma financials

Revenue TTM	$10.5 million
Gross profit TTM	$-6,836,000
Return on assets TTM	-26.55%
Return on equity TTM	-61.82%
Profit margin	-155.18%
Book value	$2.87
Market capitalisation	$66 million

TTM: trailing 12 months

Shorting aTyr Pharma shares

There are currently 884,479 aTyr Pharma shares held short by investors – that's known as aTyr Pharma's "short interest". This figure is 30.6% up from 677,271 last month.

There are a few different ways that this level of interest in shorting aTyr Pharma shares can be evaluated.

aTyr Pharma's "short interest ratio" (SIR)

aTyr Pharma's "short interest ratio" (SIR) is the quantity of aTyr Pharma shares currently shorted divided by the average quantity of aTyr Pharma shares traded daily (recently around 2.0 million). aTyr Pharma's SIR currently stands at 0.44. In other words for every 100,000 aTyr Pharma shares traded daily on the market, roughly 440 shares are currently held short.

However aTyr Pharma's short interest can also be evaluated against the total number of aTyr Pharma shares, or, against the total number of tradable aTyr Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case aTyr Pharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 aTyr Pharma shares in existence, roughly 60 shares are currently held short) or 0.0643% of the tradable shares (for every 100,000 tradable aTyr Pharma shares, roughly 64 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against aTyr Pharma.

Find out more about how you can short aTyr Pharma stock.

aTyr Pharma share dividends

We're not expecting aTyr Pharma to pay a dividend over the next 12 months.

Have aTyr Pharma's shares ever split?

aTyr Pharma's shares were split on a 1:14 basis on 30 June 2019. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your aTyr Pharma shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for aTyr Pharma shares which in turn could have impacted aTyr Pharma's share price.

aTyr Pharma share price volatility

Over the last 12 months, aTyr Pharma's shares have ranged in value from as little as $2.93 up to $7.929. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while aTyr Pharma's is 2.1164. This would suggest that aTyr Pharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.

aTyr Pharma overview

aTyr Pharma, Inc. , a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product ATYR1923 is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co. , Ltd.

Frequently asked questions

What percentage of aTyr Pharma is owned by insiders or institutions?
Currently 3.961% of aTyr Pharma shares are held by insiders and 46.173% by institutions. How many people work for aTyr Pharma?
Latest data suggests 40 work at aTyr Pharma. When does the fiscal year end for aTyr Pharma?
aTyr Pharma's fiscal year ends in December. Where is aTyr Pharma based?
aTyr Pharma's address is: 3545 John Hopkins Court, San Diego, CA, United States, 92121 What is aTyr Pharma's ISIN number?
aTyr Pharma's international securities identification number is: US0021202025 What is aTyr Pharma's CUSIP number?
aTyr Pharma's Committee on Uniform Securities Identification Procedures number is: 002120103